PURPOSE: HuR is an mRNA-binding protein that enhances the stability of certain transcripts and can regulate their translation. Elevated cytoplasmic expression of HuR protein has been linked to carcinogenesis and is associated with reduced survival in breast, ovarian, and gastric adenocarcinomas. EXPERIMENTAL DESIGN: Here, we have explored the relevance of HuR in familial breast cancer. Tumor samples were collected from patients with identified BRCA1 (n = 51) or BRCA2 (n = 47) mutations or familial non-BRCA1/2 cases (n = 525), and analyzed by immunohistochemistry. RESULTS: Among familial non-BRCA1/2 breast cancer patients, cytoplasmic HuR protein expression was present in 39.4% of the cases and was associated with estrogen receptor negativity, progesterone receptor negativity, p53 positivity, high tumor grade, and ductal type of the tumor. In multivariate analysis, cytoplasmic HuR expression was an independent marker of reduced survival in the non-BRCA1/2 group along with tumor size >2 cm, lymph node metastasis, and high histologic grade. In patients with BRCA1 or BRCA2 mutations, cytoplasmic HuR expression was more frequent (62.7% for BRCA1 and 61.7% for BRCA2) than in the non-BRCA1/2 group, but in BRCA-mutated subgroups cytoplasmic HuR expression did not associate with survival. CONCLUSIONS: Our results show that HuR is an important prognostic factor in familial breast cancer patients and may contribute to carcinogenesis in this disease.
PURPOSE:HuR is an mRNA-binding protein that enhances the stability of certain transcripts and can regulate their translation. Elevated cytoplasmic expression of HuR protein has been linked to carcinogenesis and is associated with reduced survival in breast, ovarian, and gastric adenocarcinomas. EXPERIMENTAL DESIGN: Here, we have explored the relevance of HuR in familial breast cancer. Tumor samples were collected from patients with identified BRCA1 (n = 51) or BRCA2 (n = 47) mutations or familial non-BRCA1/2 cases (n = 525), and analyzed by immunohistochemistry. RESULTS: Among familial non-BRCA1/2breast cancerpatients, cytoplasmic HuR protein expression was present in 39.4% of the cases and was associated with estrogen receptor negativity, progesterone receptor negativity, p53 positivity, high tumor grade, and ductal type of the tumor. In multivariate analysis, cytoplasmic HuR expression was an independent marker of reduced survival in the non-BRCA1/2 group along with tumor size >2 cm, lymph node metastasis, and high histologic grade. In patients with BRCA1 or BRCA2 mutations, cytoplasmic HuR expression was more frequent (62.7% for BRCA1 and 61.7% for BRCA2) than in the non-BRCA1/2 group, but in BRCA-mutated subgroups cytoplasmic HuR expression did not associate with survival. CONCLUSIONS: Our results show that HuR is an important prognostic factor in familial breast cancerpatients and may contribute to carcinogenesis in this disease.
Authors: Matthew M Gubin; Robert Calaluce; J Wade Davis; Joseph D Magee; Connie S Strouse; Daniel P Shaw; Lixin Ma; Ashley Brown; Timothy Hoffman; Tammy L Rold; Ulus Atasoy Journal: Cell Cycle Date: 2010-08-17 Impact factor: 4.534
Authors: Natalia Filippova; Xiuhua Yang; Yimin Wang; G Yancey Gillespie; Cathy Langford; Peter H King; Crystal Wheeler; L Burt Nabors Journal: Mol Cancer Res Date: 2011-04-15 Impact factor: 5.852
Authors: Robert Calaluce; Matthew M Gubin; J Wade Davis; Joseph D Magee; Jing Chen; Yuki Kuwano; Myriam Gorospe; Ulus Atasoy Journal: BMC Cancer Date: 2010-04-06 Impact factor: 4.430